Goldberg Law PC (www.Goldberglawpc.com) reminds investors in Avalanche Biotechnologies, Inc. (“Avalanche” or the “Company”) (NASDAQ: AAVL), who purchased or otherwise acquired shares between July 31, 2014 and June 15, 2015, inclusive (the “Class Period”), of the September 8, 2015 deadline to file a motion to be appointed as lead plaintiff.

If you are a shareholder who suffered a loss during the Class Period, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey, CA 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

Avalanche is a biotechnology company engaged in the development of gene therapies for patients with various ophthalmic diseases. According to the complaint, on June 15, 2015, Avalanche held a conference call to discuss their Phase IIa trial results concerning a gene therapy treatment for wet age-related macular degeneration. During the call Avalanche stated that the study was not designed to demonstrate statistically significant differences between the active and control groups. As a result, shares dropped over 56% the following day to end at $17.05 on June 16, 2015.

If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, via email at info@goldberglawpc.com, or visit our website at Goldberglawpc.com.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.